CST, 85813T, PCSK9 (D7U6L) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying PCSK9. Validated for Western Blotting,Immunoprecipitation. Available in 2 sizes. Highly specific and rigorously validated in-house, PCSK9 (D7U6L) Rabbit Monoclonal Antibody (CST #85813) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation Specificity / Sensitivity PCSK9 (D7U6L) Rabbit Monoclonal Antibody recognizes endogenous levels of total PCSK9 protein. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gln190 of human PCSK9 protein. Background The proprotein convertases (PCs) are enzymes that activate precursor proteins through proteolytic cleavage within the secretory pathway. PCs comprise several enzymes that are basic amino acid-specific proteinases (furin, PC1/3, PC2, PC4, PACE4, PC5/6, and PC7), as well as nonbasic amino acid convertases (S1P and PC9) (1). PCs have a common structure that includes an N-terminal signal peptide for secretory pathway targeting; a pro-domain that is thought to act as an intramolecular chaperone; a catalytic domain containing the active site; a P-domain that contributes to the overall folding of the enzyme by regulating stability, calcium-, and pH-dependence; and a C-terminal domain that interacts with the membrane (2). PCs act in a tissue- and substrate-specific fashion to generate an array of bioactive peptides and proteins from precursors, both in the brain and the periphery (3). Mutations in the PCSK9 gene (encoding proprotein converts subtilisin/kexin type 9, PC9) have been found to cause autosomal-dominant hypercholesterolemia. PCSK9 was therefore demonstrated to be a key factor involved in lipoprotein metabolism (4). PCSK9 acts as a chaperone protein that binds the LDL receptor (LDLR) at the cell membrane and induces LDLR lysosomal degradation rather than recycling (5). PCSK9 inhibition has since been a new therapeutic strategy for the treatment of hypercholesterolemia (6). Alternate Names convertase subtilisin/kexin type 9 preproprotein; FH3; FHCL3; HCHOLA3; LDLCQ1; NARC-1; NARC1; neural apoptosis regulated convertase 1; Neural apoptosis-regulated convertase 1; PC9; PCSK9; Proprotein convertase 9; Proprotein convertase subtilisin/kexin type 9; Subtilisin/kexin-like protease PC9 Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 65, 80 Source/Isotype: Rabbit IgG